Back to today’s briefing

Story perspectives

87% Melanoma Patients Thrive Post-Nivolumab Treatment, Study Shows

7/11/2025

46 10

Summary

Story summary

A groundbreaking study from The University of Texas MD Anderson Cancer Center reveals that 87% of stage III melanoma patients who received nivolumab and relatlimab before surgery are thriving four years later. Remarkably, 80% remain disease-free, and 95% of those with a strong treatment response show no signs of recurrence. Promising biomarkers have been identified, paving the way for improved treatment strategies.

1 of 1

Story summary

A groundbreaking study from The University of Texas MD Anderson Cancer Center reveals that 87% of stage III melanoma patients who received nivolumab and relatlimab before surgery are thriving four years later. Remarkably, 80% remain disease-free, and 95% of those with a strong treatment response show no signs of recurrence. Promising biomarkers have been identified, paving the way for improved treatment strategies.